The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

about

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.

Item

http://www.wikidata.org/entity/Q55078568

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

The heart failure burden of ty ...... ophysiology and interventions.

@en

The heart failure burden of ty ...... ophysiology and interventions.

@nl

type

Item

label

The heart failure burden of ty ...... ophysiology and interventions.

@en

The heart failure burden of ty ...... ophysiology and interventions.

@nl

prefLabel

The heart failure burden of ty ...... ophysiology and interventions.

@en

The heart failure burden of ty ...... ophysiology and interventions.

@nl

P1476

The heart failure burden of ty ...... ophysiology and interventions.

@en

P2093

Anne Pernille Ofstad

http://www.w3.org/2001/XMLSchema#string

Gisle Langslet

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

P2888

s10741-018-9685-0

P304

303-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S10741-018-9685-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lars Gullestad

Odd Erik Johansen

Dan Atar

P5008

ScienceSource

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101385071

http://www.w3.org/2001/XMLSchema#string

P698

29516230

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

heart failure

type-2 diabetes

maturity-onset diabetes of the young

P932

5937871

http://www.w3.org/2001/XMLSchema#string